Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies
Research output: Contribution to journal › Review › Research › peer-review
Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential 'antioxidant' activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.
Original language | English |
---|---|
Journal | Current Diabetes Reviews |
Volume | 12 |
Issue number | 4 |
Pages (from-to) | 331-358 |
Number of pages | 28 |
ISSN | 1573-3998 |
DOIs | |
Publication status | Published - 2016 |
- Animals, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Evidence-Based Practice, Glucagon-Like Peptide 1, Humans, Oxidative Stress, Peptides, Reactive Oxygen Species, Venoms, Journal Article, Review
Research areas
ID: 176919218